Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns

Xenon Pharmaceuticals temporarily paused enrollment in clinical trials of its experimental treatments for major depression and bipolar disorder after reports of mental and nervous system-related side effects. The safety signal creates a material development risk for the programs and could delay trial timelines and potential commercialization.